{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:21:10Z","timestamp":1793089270608,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.ppat.1008223","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000}}],"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372447"],"award-info":[{"award-number":["81372447"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972550"],"award-info":[{"award-number":["81972550"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1008223","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T18:30:25Z","timestamp":1578335425000},"page":"e1008223","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-8078","authenticated-orcid":true,"given":"Shanli","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saidu","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-1507","authenticated-orcid":true,"given":"Lifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"issue":"3","key":"ppat.1008223.ref001","first-page":"227","article-title":"The Pathogenesis of Epstein-Barr Virus Persistent Infection","volume":"3","author":"DA Thorley-lawson","year":"2013","journal-title":"Curr OpinVirol"},{"issue":"12","key":"ppat.1008223.ref002","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc.2016.92","article-title":"Epstein-Barr virus: more than 50 years old and still providing surprises","volume":"16","author":"LS Young","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ppat.1008223.ref003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.4448","article-title":"The role of Epstein-Barr virus in epithelial malignancies","volume":"235","author":"SW Tsao","year":"2015","journal-title":"J Pathol"},{"issue":"138","key":"ppat.1008223.ref004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/newbio244245a0","article-title":"EB viral genomes in epithelial nasopharyngeal carcinoma cells","volume":"244","author":"H Wolf","year":"1973","journal-title":"Nat New Biol"},{"issue":"11","key":"ppat.1008223.ref005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199509143331103","article-title":"Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma","volume":"333","author":"R Pathmanathan","year":"1995","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1008223.ref006","first-page":"443","article-title":"Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space","volume":"5","author":"A de Schryver","year":"1969","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"ppat.1008223.ref007","first-page":"225","article-title":"Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups","volume":"44","author":"W Henle","year":"1970","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"ppat.1008223.ref008","doi-asserted-by":"crossref","first-page":"e1004656","DOI":"10.1371\/journal.ppat.1004656","article-title":"LuftigMA. To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis","volume":"11","author":"AM Price","year":"2015","journal-title":"PLoS Pathog"},{"issue":"13","key":"ppat.1008223.ref009","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1128\/JVI.00422-11","article-title":"Canonical NF-\u03baB Activation Is Essential for Epstein-Barr Virus Latent Membrane Protein 1 TES2\/CTAR2 Gene Regulation","volume":"85","author":"BE Gewurz","year":"2011","journal-title":"J Virol"},{"issue":"5","key":"ppat.1008223.ref010","doi-asserted-by":"crossref","first-page":"e1004890","DOI":"10.1371\/journal.ppat.1004890","article-title":"TRAF1 Coordinates Polyubiquitin Signaling to Enhance Epstein-Barr Virus LMP1-Mediated Growth and Survival Pathway Activation","volume":"11","author":"H Greenfeld","year":"2015","journal-title":"Plos Pathog"},{"issue":"10","key":"ppat.1008223.ref011","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein-Barr virus: 40 years on","volume":"4","author":"LS Young","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ppat.1008223.ref012","doi-asserted-by":"crossref","first-page":"e01593","DOI":"10.1128\/JVI.01593-18","article-title":"A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA","volume":"93","author":"V Majerciak","year":"2019","journal-title":"J Virol"},{"key":"ppat.1008223.ref013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-230X(00)79006-3","article-title":"Epstein-Barr virus latency: LMP-2, a regulator or means for Epstein-Barr virus persistence?","volume":"79","author":"R. Longnecker","year":"2000","journal-title":"Adv Cancer Res"},{"issue":"14","key":"ppat.1008223.ref014","doi-asserted-by":"crossref","first-page":"7852","DOI":"10.1128\/JVI.78.14.7852-7860.2004","article-title":"Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen","volume":"78","author":"N Sutkowski","year":"2004","journal-title":"J Virol"},{"issue":"6","key":"ppat.1008223.ref015","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/scbi.2001.0411","article-title":"Interferon regulatory factor 7: a key cellular mediator of LMP-1 in EBV latency and transformation","volume":"11","author":"L Zhang","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"ppat.1008223.ref016","first-page":"222","article-title":"The signaling pathways of Epstein-Barr virus-encoded latent membrane protein 2A (LMP2A) in latency and cancer","volume":"14","author":"MF Pang","year":"2009","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"ppat.1008223.ref017","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1128\/JVI.01723-07","article-title":"Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection","volume":"82","author":"MP Rechsteiner","year":"2008","journal-title":"J Virol"},{"issue":"1","key":"ppat.1008223.ref018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1128\/JVI.01302-06","article-title":"Epstein-Barr Virus Latent Membrane Protein 2B (LMP2B) Modulates LMP2A Activity","volume":"81","author":"M Rovedo","year":"2007","journal-title":"J Virol"},{"issue":"12","key":"ppat.1008223.ref019","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","article-title":"Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications","volume":"584","author":"J L\u00f6fblom","year":"2010","journal-title":"FEBS Lett"},{"issue":"6","key":"ppat.1008223.ref020","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/protein\/8.6.601","article-title":"A combinatorial library of an alpha-helical bacterial receptor domain","volume":"8","author":"K Nord","year":"1995","journal-title":"Protein Eng"},{"issue":"3","key":"ppat.1008223.ref021","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1038\/emm.2017.35","article-title":"Affibody molecules as engineered protein drugs","volume":"49","author":"FY Frejd","year":"2017","journal-title":"Exp Mol Med"},{"issue":"8","key":"ppat.1008223.ref022","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","article-title":"Affibody Molecules in Biotechnological and Medical Applications","volume":"35","author":"S St\u00e5hl","year":"2017","journal-title":"Trends Biotechnol"},{"issue":"6","key":"ppat.1008223.ref023","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3892\/ijo.2016.3721","article-title":"Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with99mTc using a peptide-based cysteine-containing chelator","volume":"49","author":"KG Andersson","year":"2016","journal-title":"Int J Oncol"},{"key":"ppat.1008223.ref024","first-page":"7","article-title":"Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors","volume":"18","author":"M Oroujeni","year":"2018","journal-title":"Cells"},{"issue":"8","key":"ppat.1008223.ref025","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","article-title":"Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule","volume":"66","author":"A Orlova","year":"2006","journal-title":"Cancer Res"},{"key":"ppat.1008223.ref026","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7150\/thno.13502","article-title":"Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET\/CT","volume":"6","author":"J S\u00f6rensen","year":"2016","journal-title":"Theranostics"},{"key":"ppat.1008223.ref027","doi-asserted-by":"crossref","first-page":"e62791","DOI":"10.1371\/journal.pone.0062791","article-title":"Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification","volume":"8","author":"M Malm","year":"2013","journal-title":"Plos One"},{"key":"ppat.1008223.ref028","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.molpharmaceut.6b00919","article-title":"Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells","volume":"14","author":"JS Schardt","year":"2017","journal-title":"Mol Pharm"},{"issue":"7","key":"ppat.1008223.ref029","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.chembiol.2011.05.011","article-title":"The Development of Peptide-Based Tools for the Analysis of Angiogenesis","volume":"18","author":"A Fedorova","year":"2011","journal-title":"Chem Biol"},{"issue":"45","key":"ppat.1008223.ref030","doi-asserted-by":"crossref","first-page":"73995","DOI":"10.18632\/oncotarget.12174","article-title":"Generation of affibody molecules specific for HPV16 E7 recognition","volume":"7","author":"X Xue","year":"2016","journal-title":"Oncotarget"},{"key":"ppat.1008223.ref031","article-title":"Bispecific affibody molecule targeting HPV16 and HPV18E7 oncoproteins for enhanced molecular imaging of cervical cancer","author":"S Zhu","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"issue":"Pt 1","key":"ppat.1008223.ref032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/bj3070029","article-title":"Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor","volume":"307","author":"RJ Kreitman","year":"1995","journal-title":"Biochem J"},{"key":"ppat.1008223.ref033","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3389\/fmicb.2015.00963","article-title":"Pseudomonas Exotoxin A: optimized by evolution for effective killing","volume":"6","author":"M Michalska","year":"2015","journal-title":"Front Microbiol"},{"issue":"1","key":"ppat.1008223.ref034","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12390","article-title":"Immunogenicity of therapeutic recombinant immunotoxins","volume":"270","author":"R Mazor","year":"2016","journal-title":"Immunol Rev"},{"issue":"2","key":"ppat.1008223.ref035","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"LA Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"ppat.1008223.ref036","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and\/or Locally Recurrent Nasopharyngeal Carcinoma","volume":"22","author":"WK Chia","year":"2014","journal-title":"Mol Ther"},{"issue":"11","key":"ppat.1008223.ref037","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5732\/cjc.013.10148","article-title":"Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis","volume":"32","author":"MY Chen","year":"2013","journal-title":"Chin J Cancer"},{"issue":"1","key":"ppat.1008223.ref038","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1711650105","article-title":"Epstein-Barr virus and carcinomas: undifferentiated carcinomas but not squamous cell carcinomas of the nasopharynx are regularly associated with the virus","volume":"165","author":"G Niedobitek","year":"1991","journal-title":"J Pathol"},{"issue":"5","key":"ppat.1008223.ref039","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1128\/JVI.64.5.2319-2326.1990","article-title":"A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1","volume":"64","author":"R Longnecker","year":"1990","journal-title":"J Virol"},{"issue":"2","key":"ppat.1008223.ref040","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11262-007-0118-8","article-title":"Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2","volume":"35","author":"MJ Tomaszewski-flick","year":"2007","journal-title":"Virus Genes"},{"key":"ppat.1008223.ref041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-1-61779-921-1_7","article-title":"Engineering of affibody molecules for therapy and diagnostics","volume":"899","author":"J Feldwisch","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"2","key":"ppat.1008223.ref042","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00726-014-1859-z","article-title":"Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression","volume":"47","author":"B Mitran","year":"2015","journal-title":"Amino acids"},{"issue":"Pt 2","key":"ppat.1008223.ref043","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/BA20060016","article-title":"Selection and characterization of an HIV-1 gp120-binding affibody ligand","volume":"45","author":"M Wikman","year":"2006","journal-title":"Biotechnol Appl Biochem"},{"issue":"5","key":"ppat.1008223.ref044","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.113.131243","article-title":"First-in-human molecular imaging of HER2 expression in breast cancermetastases using the 111In-ABY-025 affibody molecule","volume":"55","author":"J S\u00f6rensen","year":"2014","journal-title":"J Nucl Med"},{"issue":"1","key":"ppat.1008223.ref045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13550-016-0213-8","article-title":"Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake","volume":"6","author":"Q Cheng","year":"2016","journal-title":"EJNMMI Res"},{"issue":"9","key":"ppat.1008223.ref046","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.3390\/cells7090141","article-title":"Preclinical Evaluation of [68Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors","volume":"7","author":"M Oroujeni","year":"2018","journal-title":"Cells"},{"key":"ppat.1008223.ref047","doi-asserted-by":"crossref","first-page":"15226","DOI":"10.1038\/srep15226","article-title":"Affibody-mediated PET imaging of HER3 expression in malignant tumours","volume":"5","author":"M Rosestedt","year":"2015","journal-title":"Sci Rep"},{"issue":"6","key":"ppat.1008223.ref048","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","author":"RP Baum","year":"2010","journal-title":"J Nucl Med"},{"issue":"8","key":"ppat.1008223.ref049","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CJI.0b013e3181ad4d5d","article-title":"Affitoxin- A Novel Recombinant, HER2-Specific, Anti-Cancer Agent for Targeted Therapy of HER2-","volume":"32","author":"R Zielinski","year":"2009","journal-title":"Positive Tumors. J Immunother"},{"issue":"15","key":"ppat.1008223.ref050","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1158\/1078-0432.CCR-10-2887","article-title":"HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors","volume":"17","author":"R Zielinski","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ppat.1008223.ref051","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/IAI.15.1.138-144.1977","article-title":"Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate ribosylationof mammalian elongation factor 2 in vitro and in vivo","volume":"15","author":"BH Iglewski","year":"1977","journal-title":"Infect Immun"},{"issue":"2","key":"ppat.1008223.ref052","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2008.10.027","article-title":"Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line","volume":"377","author":"L Ekerljung","year":"2008","journal-title":"Biochem Biophys Res Commun."},{"issue":"6","key":"ppat.1008223.ref053","doi-asserted-by":"crossref","first-page":"e40023","DOI":"10.1371\/journal.pone.0040023","article-title":"Cellular effects of HER3-specific affibody molecules","volume":"7","author":"L G\u00f6string","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"ppat.1008223.ref054","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/vim.2010.0092","article-title":"Identification and characterization of novel B-cell epitopes within EBV latent membrane protein 2 (LMP2)","volume":"24","author":"X Xue","year":"2011","journal-title":"Viral Immunol"},{"key":"ppat.1008223.ref055","doi-asserted-by":"crossref","first-page":"652147","DOI":"10.4061\/2011\/652147","article-title":"Generation and Characterization ofan scFv Directed against Site II of Rabies Glycoprotein","volume":"2011","author":"SM Aavula","year":"2011","journal-title":"Biotechnol Res Int"},{"issue":"1","key":"ppat.1008223.ref056","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pep.2005.04.004","article-title":"Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli","volume":"44","author":"S Song","year":"2005","journal-title":"Protein Expr Purif"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1008223","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1008223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T20:16:31Z","timestamp":1722284191000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1008223"}},"subtitle":[],"editor":[{"given":"Fanxiu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1008223","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.ppat.1008223","asserted-by":"object"}]},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]}}}